Use of AAM for Correction of Age Related Volume Deficits in the Face

A Multi-Phase, Prospective, Multi-Center, Single-Blind, Clinical Study to Evaluate the Safety and Efficacy of Allograft Adipose Matrix (AAM) and Diluted AAM for Pre-Jowl and Malar Augmentation to Correct Age Related Volume Deficit in the Face

The purpose of this study is to evaluate Allograft Adipose Matrix (AAM) in the face of people with age-related volume deficit - fat loss. AAM is a tissue used to correct fat loss. Participation in this study requires injections for placing AAM in the bilateral pre-jowl and malar areas of the face. The research will tell whether AAM is effective in maintaining mid-face fullness and whether the appearance of the skin improves after injection.

Study Overview

• Status: Completed
• Conditions: Age-Related Atrophy
• Intervention / Treatment: Procedure: AAM

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Florida
    • Boca Raton, Florida, United States, 33431
      • Aesthetic Eyelid Plastic Surgery
  • Tennessee
    • Nashville, Tennessee, United States, 37215
      • Tennessee Clinical Research Center
  • Texas
    • Dallas, Texas, United States, 75231
      • Dallas Plastic Surgery Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 28 years to 68 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Men or women, 30-70 years of age
2. Has overall mid-facial volume deficit of Grade 3 or 4 on Medicis Midface Volume Scale (MMVS)
3. Willingness and ability to provide written informed consent
4. Has not had AAM injected above the neck
5. Ability to understand and comply with the requirements of the study
6. Negative urine pregnancy test results at the time of study entry (if applicable).
7. Willingness to stay on consistent and current skin care regimen for the duration of the study
8. Willingness to maintain consistent and current diet and exercise for the duration of the study
9. Willingness to forego any cosmetic augmentation procedure for the duration of the study
10. Willingness to be photographed for educational, medical publication and other non-commercial purposes
11. Has BMI ≥18 and ≤30

Exclusion Criteria:

1. A subject with any uncontrolled systemic disease.
2. A subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study.
3. A subject with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
4. Women that are pregnant, nursing, or planning a pregnancy during the duration of the study
5. A subject that has had AAM injected above the neck
6. A subject unwilling to be photographed for educational, medical publication and other non-commercial purposes
7. A subject with a history of diabetes
8. A subject with known hypersensitivity to any of the components of AAM
9. A subject that has had, or who knowingly will have, dental work +/- 4 weeks prior to, or following AAM injection
10. A subject using any systemic corticosteroid or immunosuppressive medications within 30 days prior to treatment and topical steroids on the face within 14 days prior to treatment and throughout the study
11. A subject that has participated in another research study within 30 days of enrollment in this study
12. A subject that is unwilling to forego any cosmetic augmentation treatment for the duration of the study
13. A subject that has been treated with Botulinum Toxin below the orbital rim within 6 months of study entry.
14. A subject that is unwilling to forego cosmetic facial treatments for the duration of the study
15. A subject that has received Sculptra in the treatment area
16. A subject that has received dermal filler in the treatment area within 2 years prior to randomization
17. A subject that has previously undergone mid-face cosmetic plastic surgery, tissue grafting, or tissue augmentation with silicone, semi-permanent fillers or fat
18. A subject that has previously undergone laser resurfacing, intense pulsed light treatment, chemical peel, or other ablative or non-ablative treatment within 6 months
19. Subject is immunocompromised or immunosuppressed
20. History of keloid formation or hypertrophic scars
21. NSAID or Aspirin, other than a stable low dose aspirin regimen, within 1 week (7 days) prior to treatment
22. Concomitant anticoagulant therapy, antiplatelet therapy, or history of bleeding disorders or connective tissue disorders
23. A subject with recent excessive facial exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing)
24. A subject with a recent history or active presence of any facial skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e. moderate to severe acne vulgaris, atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, excessive facial hair or coloration)
25. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study
26. A subject not deemed to be enrolled at the discretion of the surgeon investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Allograft Adipose Matrix (AAM) 1.0	Procedure: AAM; Subcutaneous injection procedure
Active Comparator: Allograft Adipose Matrix (AAM) Diluted	Procedure: AAM; Subcutaneous injection procedure

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Volume change for the treated areas using the validated 4 point MEDICIS Mid-Face Volume Scale Assessment (MMVSA) at 24 weeks post-treatment compared to pre-treatment	MMVSA measures facial volume deficit, ranging from 1 (fairly full midface) to 4 (substantial loss of fullness in the midface area). Lower values represent a better outcome.	24 weeks
Three-D facial photography (Canfield) with computation of volume changes at 24 weeks compared to pre-treatment.		24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of effectiveness when the average of the Evaluating Investigators' live assessments of the MMVSA scale will return to, or be worse than, the pre-treatment level over 24 weeks post-treatment.	MMVSA measures facial volume deficit, ranging from 1 (fairly full midface) to 4 (substantial loss of fullness in the midface area). Lower values represent a better outcome.	24 weeks
Volume change assessments using the Global Aesthetic Improvement Scale (GAIS) at 24 weeks post-treatment compared to pre-treatment	GAIS rates improvement in appearance. Scores range from 0 (worse) to 4 (very much improved). Higher values represent a better outcome.	24 weeks

Collaborators and Investigators

• Sponsor: Musculoskeletal Transplant Foundation

Study record dates

Study Major Dates

• Study Start (Actual): August 27, 2018
• Primary Completion (Actual): July 12, 2019
• Study Completion (Actual): July 12, 2019

Study Registration Dates

• First Submitted: August 28, 2018
• First Submitted That Met QC Criteria: August 28, 2018
• First Posted (Actual): August 29, 2018

Study Record Updates

• Last Update Posted (Actual): May 11, 2021
• Last Update Submitted That Met QC Criteria: May 7, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Atrophy
• Other Study ID Numbers: MTF 18-04-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No